With over 16 years of experience in cell biology, oncology drug discovery, and translational science, I support biotech and pharma teams in moving programs from early discovery toward preclinical readiness. My work focuses on building robust screening and validation strategies that improve decision quality before costly downstream development.
I have led teams across major organizations including Takeda and Novartis, with responsibility for early target discovery, functional genomics, and advanced assay development. I specialize in high-throughput assay design, CRISPR and small-molecule screening, and complex 3D/co-culture disease models, especially in oncology and immuno-oncology.
My work includes translational platform development, tumor microenvironment modeling, and preclinical pharmacology support for emerging therapeutics. I help teams turn discovery challenges into actionable experimental strategies with a strong focus on biological relevance, scalability, and speed to decision.
